安第斯病毒相关汉坦病毒心肺综合征的重症负担与结局时间趋势:智利全国队列
该研究利用智利31家医院2019—2024年诊断相关组数据库,纳入215例安第斯病毒相关汉坦病毒心肺综合征(HCPS)住院患者,按最大呼吸支持方式分层。148例需呼吸支持者中,14.2%接受无创通气、36.5%接受有创机械通气、49.3%需要ECMO。住院中位时长8天,院内死亡率20.5%;机械通气者病死率29.6%,ECMO者32.9%。
要点
- 215例HCPS住院患者院内死亡率20.5%,中位住院时长8天。
- 需呼吸支持者148例中49.3%需要ECMO,36.5%接受有创机械通气,14.2%接受无创通气。
- 机械通气患者病死率29.6%,ECMO患者病死率32.9%。
- 研究强调安第斯病毒HCPS仍伴随高死亡率与大量呼吸支持需求,尤其机械通气与ECMO。
适用人群与场景
- 按最大呼吸支持方式分层:无呼吸支持、无创通气、有创机械通气、ECMO。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:全国性队列研究,基于诊断相关组(DRG)数据库,覆盖智利31家医院,纳入215例HCPS患者。
- 呼吸支持分布:148例需呼吸支持者中,14.2%接受无创通气,36.5%接受有创机械通气,49.3%需要ECMO。
- 主要结局:住院中位时长8天(3-15天),院内死亡率20.5%;机械通气者病死率29.6%,ECMO者病死率32.9%。
证据类型、等级与局限
- 证据类型:基于行政数据库的全国性回顾性队列研究,样本量215例,覆盖31家医院。
- 局限:原文未明确提及,但设计上为回顾性、基于DRG数据库,可能存在编码偏倚与混杂。
对床旁实践的改变
- 提示安第斯病毒HCPS患者常需高级呼吸支持(机械通气或ECMO),ICU应备有ECMO资源并关注高病死率。
- 大流行期HCPS院内死亡风险升高,提示在呼吸道传染病流行期需加强HCPS的识别与重症救治能力。
指南或共识出处
- Intensive Care Med(来源期刊)
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Andes virus causes hantavirus cardiopulmonary syndrome (HCPS), a severe disease found in central and southern parts of Chile and Argentina. Recently a case-outbreak of HCPS was reported on a cruise ship, therefore contemporary data on organ support and outcomes is required. The objective of this study was to assess organ support use and patient outcomes in patients admitted with HCPS.
METHODS: We used the Diagnosis-Related Groups (DGR) database to analyse patients admitted in 31 Chilean hospitals between January 1, 2019, and December 31, 2024. They were stratified by the maximal respiratory support received: no respiratory support, non-invasive ventilation (NIV), invasive mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO). Hospital length of stay (LOS) and in-hospital mortality were the main outcomes assessed. In-hospital mortality was further analysed by pre-COVID-19 pandemic, pandemic, and post-pandemic periods.
RESULTS: A total of 215 patients with HCPS were identified, of whom 69.3% were males and 87% were adults. Of 148 patients who required respiratory support, 14.2% received NIV, 36.5% received MV and 49.3% required ECMO. Hospital LOS was 8 [3-15] days and in-hospital mortality was 20.5%. Case fatality rates were 29.6% for patients receiving MV and 32.9% for those receiving ECMO. The pandemic period was independently associated with higher in-hospital mortality (aOR 2.73 [1.06-7.63]; p = 0.045).
CONCLUSION: HCPS caused by Andes virus remains associated with high in-hospital mortality and substantial amounts of respiratory support, particularly MV and ECMO. Moreover, the COVID-19 pandemic was associated with a significant increase in HCPS mortality.
参考来源
- Meza-Fuentes G, Delgado I, Vial PA, et al. Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort. Intensive Care Med. 2026. PMID: 42684407. doi:10.1007/s00134-026-08599-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。